Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in JapanBusiness Wire • 09/21/21
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 InsertionBenzinga • 09/16/21
Takeda's EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLCBusiness Wire • 09/15/21
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema AttacksBusiness Wire • 08/05/21
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVieBusiness Wire • 08/01/21
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/31/21
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine CandidateGlobeNewsWire • 07/30/21
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline ProgressBusiness Wire • 07/30/21